677 related articles for article (PubMed ID: 20416374)
1. Heparin-derived heparan sulfate mimics to modulate heparan sulfate-protein interaction in inflammation and cancer.
Casu B; Naggi A; Torri G
Matrix Biol; 2010 Jul; 29(6):442-52. PubMed ID: 20416374
[TBL] [Abstract][Full Text] [Related]
2. Differential structural requirements of heparin and heparan sulfate proteoglycans that promote binding of basic fibroblast growth factor to its receptor.
Aviezer D; Levy E; Safran M; Svahn C; Buddecke E; Schmidt A; David G; Vlodavsky I; Yayon A
J Biol Chem; 1994 Jan; 269(1):114-21. PubMed ID: 8276782
[TBL] [Abstract][Full Text] [Related]
3. Heparanase and a synthetic peptide of heparan sulfate-interacting protein recognize common sites on cell surface and extracellular matrix heparan sulfate.
Marchetti D; Liu S; Spohn WC; Carson DD
J Biol Chem; 1997 Jun; 272(25):15891-7. PubMed ID: 9188488
[TBL] [Abstract][Full Text] [Related]
4. Biosynthetic oligosaccharide libraries for identification of protein-binding heparan sulfate motifs. Exploring the structural diversity by screening for fibroblast growth factor (FGF)1 and FGF2 binding.
Jemth P; Kreuger J; Kusche-Gullberg M; Sturiale L; Giménez-Gallego G; Lindahl U
J Biol Chem; 2002 Aug; 277(34):30567-73. PubMed ID: 12058038
[TBL] [Abstract][Full Text] [Related]
5. Use of sulfated linked cyclitols as heparan sulfate mimetics to probe the heparin/heparan sulfate binding specificity of proteins.
Freeman C; Liu L; Banwell MG; Brown KJ; Bezos A; Ferro V; Parish CR
J Biol Chem; 2005 Mar; 280(10):8842-9. PubMed ID: 15632177
[TBL] [Abstract][Full Text] [Related]
6. Minimum FGF2 binding structural requirements of heparin and heparan sulfate oligosaccharides as determined by NMR spectroscopy.
Guglier S; Hricovíni M; Raman R; Polito L; Torri G; Casu B; Sasisekharan R; Guerrini M
Biochemistry; 2008 Dec; 47(52):13862-9. PubMed ID: 19117094
[TBL] [Abstract][Full Text] [Related]
7. Minimal heparin/heparan sulfate sequences for binding to fibroblast growth factor-1.
Guerrini M; Agulles T; Bisio A; Hricovini M; Lay L; Naggi A; Poletti L; Sturiale L; Torri G; Casu B
Biochem Biophys Res Commun; 2002 Mar; 292(1):222-30. PubMed ID: 11890696
[TBL] [Abstract][Full Text] [Related]
8. Highly sulfated nonreducing end-derived heparan sulfate domains bind fibroblast growth factor-2 with high affinity and are enriched in biologically active fractions.
Naimy H; Buczek-Thomas JA; Nugent MA; Leymarie N; Zaia J
J Biol Chem; 2011 Jun; 286(22):19311-9. PubMed ID: 21471211
[TBL] [Abstract][Full Text] [Related]
9. Cell surface syndecan-1 on distinct cell types differs in fine structure and ligand binding of its heparan sulfate chains.
Kato M; Wang H; Bernfield M; Gallagher JT; Turnbull JE
J Biol Chem; 1994 Jul; 269(29):18881-90. PubMed ID: 8034644
[TBL] [Abstract][Full Text] [Related]
10. Modulation of the heparanase-inhibiting activity of heparin through selective desulfation, graded N-acetylation, and glycol splitting.
Naggi A; Casu B; Perez M; Torri G; Cassinelli G; Penco S; Pisano C; Giannini G; Ishai-Michaeli R; Vlodavsky I
J Biol Chem; 2005 Apr; 280(13):12103-13. PubMed ID: 15647251
[TBL] [Abstract][Full Text] [Related]
11. Compositional analysis of heparin/heparan sulfate interacting with fibroblast growth factor.fibroblast growth factor receptor complexes.
Zhang F; Zhang Z; Lin X; Beenken A; Eliseenkova AV; Mohammadi M; Linhardt RJ
Biochemistry; 2009 Sep; 48(35):8379-86. PubMed ID: 19591432
[TBL] [Abstract][Full Text] [Related]
12. Histidine-rich glycoprotein and platelet factor 4 mask heparan sulfate proteoglycans recognized by acidic and basic fibroblast growth factor.
Brown KJ; Parish CR
Biochemistry; 1994 Nov; 33(46):13918-27. PubMed ID: 7524669
[TBL] [Abstract][Full Text] [Related]
13. Interaction of thrombospondin-1 and heparan sulfate from endothelial cells. Structural requirements of heparan sulfate.
Feitsma K; Hausser H; Robenek H; Kresse H; Vischer P
J Biol Chem; 2000 Mar; 275(13):9396-402. PubMed ID: 10734084
[TBL] [Abstract][Full Text] [Related]
14. Heparin, heparan sulfate and heparanase in inflammatory reactions.
Li JP; Vlodavsky I
Thromb Haemost; 2009 Nov; 102(5):823-8. PubMed ID: 19888515
[TBL] [Abstract][Full Text] [Related]
15. Comparable stabilisation, structural changes and activities can be induced in FGF by a variety of HS and non-GAG analogues: implications for sequence-activity relationships.
Rudd TR; Uniewicz KA; Ori A; Guimond SE; Skidmore MA; Gaudesi D; Xu R; Turnbull JE; Guerrini M; Torri G; Siligardi G; Wilkinson MC; Fernig DG; Yates EA
Org Biomol Chem; 2010 Dec; 8(23):5390-7. PubMed ID: 20865198
[TBL] [Abstract][Full Text] [Related]
16. Heparan sulfate and heparin interactions with proteins.
Meneghetti MC; Hughes AJ; Rudd TR; Nader HB; Powell AK; Yates EA; Lima MA
J R Soc Interface; 2015 Sep; 12(110):0589. PubMed ID: 26289657
[TBL] [Abstract][Full Text] [Related]
17. FGF binding and FGF receptor activation by synthetic heparan-derived di- and trisaccharides.
Ornitz DM; Herr AB; Nilsson M; Westman J; Svahn CM; Waksman G
Science; 1995 Apr; 268(5209):432-6. PubMed ID: 7536345
[TBL] [Abstract][Full Text] [Related]
18. Different affinities of glycosaminoglycan oligosaccharides for monomeric and dimeric interleukin-8: a model for chemokine regulation at inflammatory sites.
Goger B; Halden Y; Rek A; Mösl R; Pye D; Gallagher J; Kungl AJ
Biochemistry; 2002 Feb; 41(5):1640-6. PubMed ID: 11814358
[TBL] [Abstract][Full Text] [Related]
19. Differential interactions of heparin and heparan sulfate glycosaminoglycans with the selectins. Implications for the use of unfractionated and low molecular weight heparins as therapeutic agents.
Koenig A; Norgard-Sumnicht K; Linhardt R; Varki A
J Clin Invest; 1998 Feb; 101(4):877-89. PubMed ID: 9466983
[TBL] [Abstract][Full Text] [Related]
20. Interaction of hepatocyte growth factor with heparan sulfate. Elucidation of the major heparan sulfate structural determinants.
Lyon M; Deakin JA; Mizuno K; Nakamura T; Gallagher JT
J Biol Chem; 1994 Apr; 269(15):11216-23. PubMed ID: 8157651
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
